Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naproxen/pregabalin conjugate - Xgene Pharmaceutical

Next Previous
X
Search
Drug Profile

Naproxen/pregabalin conjugate - Xgene Pharmaceutical

Alternative Names: XG 005; XG004 03; XG005 01; XG005 02; XG005 03

Latest Information Update: 03 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xgene Pharmaceutical
  • Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Antipyretics; Antirheumatics; Anxiolytics; Drug conjugates; Gabapentinoids; Naphthaleneacetic acids; Neuroprotectants; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators; Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Postoperative pain
  • Phase II Acute pain; Cancer pain; Pain
  • Phase I/II Back pain; Neuropathic pain
  • No development reported Diabetic neuropathies

Most Recent Events

  • 31 Dec 2024 Efficacy and adverse events data from phase-II/III trial in Postoperative pain released by Xgene Pharmaceutical
  • 25 Oct 2024 Xgene Pharmaceutical completes the phase II/III trial in Postoperative pain in USA (PO)
  • 08 Aug 2024 Phase-II clinical trials in Cancer pain in Taiwan, China (Mainland China) (PO), prior to August 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top